Buscol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Buscol

What is Buscol?

Buscol is a medication categorized as an antispasmodic agent. It is primarily used to relieve cramps and spasms affecting the smooth muscles of the gastrointestinal and genitourinary tracts. By targeting the involuntary muscles in these areas, it helps to manage discomfort associated with various digestive and abdominal conditions.

Mechanism of Action

The active component in Buscol works by blocking the action of acetylcholine, a neurotransmitter that signals muscles to contract. This anticholinergic effect allows the smooth muscles in the stomach, intestines, and bladder to relax. Unlike some other medications that affect the entire central nervous system, this agent is designed to act locally on the peripheral nervous system, specifically targeting the site of the spasm.

Common Applications

Buscol is frequently utilized to address symptoms related to functional bowel disorders. Its primary role is to ease the physical tension in the abdomen, which may include:

  • Gastrointestinal Spasms: Relaxing the muscles of the stomach and intestines to alleviate cramping.
  • Irritable Bowel Syndrome (IBS): Assisting in the management of abdominal pain and discomfort linked to irregular muscle contractions.
  • Bladder and Urinary Tract Spasms: Reducing involuntary contractions in the urinary system.
  • Biliary Colic: Providing relief from spasms in the bile ducts.

Physical Characteristics

As a therapeutic product, Buscol is most commonly found in oral tablet form. It is formulated to be absorbed by the body in a manner that facilitates targeted relief of smooth muscle tension without significant sedative effects.

What side effects are possible with Buscol?

Possible Side Effects and Safety Information for Buscol

The official safety profile for Hyoscine Butylbromide (Buscol) is defined by its anticholinergic effects, with adverse reactions categorized by frequency and the physiological system affected. This information is derived from government regulatory documents, such as the Summary of Product Characteristics (SmPC).

Classification Examples of Officially Documented Adverse Reactions
Common (1/100 to < 1/10) Dry mouth, Dyshidrosis (disorder of sweating)
Uncommon (1/1,000 to < 1/100) Tachycardia (increased heart rate), Dizziness, Skin reactions (e.g., urticaria)
Rare (1/10,000 to < 1/1,000) Accommodation disorders (visual disturbance), Urinary retention
Not Known (Frequency cannot be estimated) Anaphylactic shock, Angioedema, Dyspnoea (difficulty breathing)

Serious adverse reactions, though classified as Not Known in frequency, include severe hypersensitivity events such as Anaphylactic shock and Angioedema. These are classified under Immune System Disorders in regulatory documentation.

Safety Restrictions and Limitations

Official labeling mandates safety restrictions for use in individuals with certain pre-existing conditions (contraindications). These restrictions include narrow-angle glaucoma, tachyarrhythmia, myasthenia gravis, and conditions that increase the risk of urinary retention, such as prostatic hypertrophy. Furthermore, limitations apply in cases of mechanical stenoses of the gastrointestinal tract and paralytic or obstructive ileus. Use is also subject to consideration in specific populations, with older adults noted for increased sensitivity to anticholinergic effects like urinary retention. Concomitant use with other anticholinergic medicines may increase the frequency or severity of typical adverse reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Hyoscine Butylbromide is characterized by an extreme exaggeration of its anticholinergic properties, as documented in regulatory prescribing information. Officially documented clinical manifestations that may occur include tachycardia (a fast heart rate), dry mouth, urinary retention, reddening of the skin (flushing), and transient visual disturbances, such as accommodation disorders. Inhibition of gastrointestinal tract movement and slight drowsiness have also been noted in documented cases.

Required Emergency Actions

Severe overdose can lead to life-threatening complications, including respiratory paralysis or severe cardiovascular compromise. Because of this potential for serious systemic effects, regulatory authorities mandate that individuals must seek urgent medical attention immediately upon any suspicion of overdosage.

Management and Supportive Care

Medical management focuses on symptomatic and supportive treatment. The official product information specifies that clinical overdosage symptoms are counteracted by a class of agents known as parasympathomimetics. In cases of severe respiratory depression, intubation and artificial respiration should be considered. Other necessary procedural steps may include catheterisation for urinary retention and administering activated charcoal following acute oral exposure. A specific instruction exists for patients with glaucoma, requiring the local use of Pilocarpine to manage acute eye symptoms.

Therapeutic Uses of Buscol

What Buscol Treats: Main Uses and Benefits

Buscol (hyoscine butylbromide) is commonly used to help with symptoms related to physical discomfort and cramping, particularly where symptoms of increased neurological or muscular activity, such as spasms, are involved. This medicine is relevant for easing the discomfort associated with a range of conditions presenting with systemic or localized discomfort.

The medicine is applied in addressing spasms of the gastrointestinal tract and the genito-urinary tract. Common indications include pain from muscle spasms in the stomach and intestines, spasms of the biliary tract, and spasms of the urinary tract.

This medicine may assist with the symptomatic relief of Irritable Bowel Syndrome (IBS), a condition involving episodic or fluctuating manifestations. When symptoms become more disruptive during flare-ups, the active ingredient supports patients by helping to ease the overall symptom burden. It is applied in scenarios where additional management of discomfort is required and where supportive symptom management is appropriate.

This medicine assists with maintaining functional stability during periods of heightened symptoms, which contributes to easing the overall symptom load and supports general well-being.

Quick Fact: Relief for Painful Spasms and Cramping

Eligibility and Restrictions for Use

This section outlines the official population eligibility for Buscol (Hyoscine Butylbromide) as defined by government regulatory documents, including groups who are permitted, restricted, or contraindicated from using the medicine.

Populations Strictly Contraindicated

Use is contraindicated in patients with specific conditions, primarily due to the drug's anticholinergic properties or its effect on muscle motility. Absolute contraindications include: untreated narrow-angle glaucoma, myasthenia gravis, megacolon, and mechanical obstructions of the gastrointestinal tract (e.g., paralytic or obstructive ileus or stenosis).

Restricted or Conditional Use

Category Official Regulatory Status
Pediatric Use Oral tablets are not recommended for children typically under 6 years of age, though eligibility varies by formulation.
Pregnancy/Lactation Use is not recommended during either state as a precautionary measure due to limited or insufficient human data on safety and excretion.
Comorbidities Parenteral administration is contraindicated in patients with tachycardia and requires caution in those susceptible to urinary retention or with pre-existing cardiac conditions.

Eligibility is limited to adults and older children without these absolute contraindications, and use in special populations is subject to specific regulatory limitations.

What should I know about interactions with other medicines?

Buscol's interaction profile is primarily defined by its anticholinergic activity, which may be intensified when taken with other medicines that also possess similar effects. This can lead to an additive increase in side effects.

Drugs that intensify effects

Concomitant use with the following classes of medicinal products may intensify the anticholinergic effect:

  • Antidepressants: Specifically tri- and tetracyclic agents.
  • Antihistamines: Medications commonly used for allergies.
  • Antipsychotics: Certain agents like phenothiazines and butyrophenones.
  • Other Anticholinergics: Including atropine-like compounds such as tiotropium, ipratropium, and amantadine.
  • Heart Medications: Including quinidine and disopyramide.

Additionally, the tachycardic effects of beta-adrenergic agents may be enhanced by Buscol, which is a consideration for patients with cardiovascular conditions.

Drugs that diminish effects

Buscol may have an antagonistic effect with certain medications that promote gastrointestinal movement, such as the dopamine antagonists metoclopramide and domperidone. Combining these can lead to a diminution of effects on the digestive tract for both drugs.

Procedural Constraint

If Buscol is administered by injection, the intramuscular route should be avoided in patients receiving anticoagulant drugs due to the risk of haematoma. Subcutaneous or intravenous administration may be used instead.

Mechanism of Action

How Buscol Works

The mechanism of Hyoscine Butylbromide is defined by its precise, chemically restricted action on the autonomic control systems that regulate the internal organs.

Targeted Blockade of Visceral Acetylcholine Receptors

This mechanism is initiated at the molecular level where the drug functions as a competitive antagonist, establishing a high-affinity block on Muscarinic Acetylcholine Receptors located on the smooth muscle cells of the gastrointestinal and genitourinary tracts. By intercepting the nerve signal from the parasympathetic pathway, the drug prevents the necessary internal cascade that uses Calcium (Ca^2+) to initiate contraction. The resulting functional consequence is the spasmolytic effect, which promotes a sustained reduction in smooth muscle tone.

️ Structural Constraint for Peripheral Action

The action of the mechanism is secured by the drug's unique chemical structure as a quaternary ammonium compound. This feature renders the molecule highly polar, ensuring it cannot readily cross the blood-brain barrier (BBB). This structural constraint causes the drug's activity to be restricted almost exclusively to the peripheral visceral targets, preventing the molecule from binding to CNS receptors.

️ Functional Limitation to Cholinergic Drive

The primary mechanism is functionally applicable in contexts where muscle hyperactivity is driven by an excessive cholinergic mediator system. However, the mechanism's scope is restricted to the specific biological targets; it is physiologically constrained in situations where the smooth muscle contraction is primarily driven by non-cholinergic mechanical forces or alternative signaling pathways that override the receptor blockade.

Dosage and Administration Information

How to Use Buscol: Administration Guidelines

The administration of Buscol (Hyoscine Butylbromide) is standardized by its formulation, which includes oral tablets for general use and a sterile solution for injection for acute needs. The injection is approved for intravenous (IV), intramuscular (IM), and subcutaneous (SC) routes. IV administration must be performed slowly.

Dosing and Frequency

Dosing regimens define distinct patterns for each route:

Administration Type Standard Adult Regimen Frequency / Context
Oral (10 mg tablets) 10 mg to 20 mg per dose Taken 3 to 5 times daily for short-course management.
Parenteral (Injection) 20 mg to 40 mg per single dose Intermittent, repeatable after 30 minutes in acute spasm. Maximum is 100 mg per day.

Administration Requirements

Oral tablets must be swallowed whole with water; they should not be crushed or chewed. The tablets may be taken with or without food. For the injection, dilution with standard solutions like sodium chloride 0.9% may be performed. The IM route is structurally restricted in patients on anticoagulant therapy, with the IV or SC routes specified as alternatives.

Population and Duration

Instructions specify the oral form for children over 6 years of age, while parenteral dosing for children is based on body weight, typically 0.3–0.6 mg/kg. No explicit dose adjustment is typically required for older adults or in cases of renal impairment. The medicine is structurally constrained to short-term symptomatic management and must not be taken continuously on a daily basis for prolonged periods unless the underlying cause of the pain has been clinically investigated.

Recent Clinical Evidence

Research evidence / Overview of studies for Buscol


Evidence for Acute Gastrointestinal Spasms and Colic

Controlled studies, including Randomized Controlled Trials (RCTs), were used in research exploring short-term symptom changes in acute settings. These studies often involved the injectable form of the medicine and were applied in research contexts involving fluctuating or unstable symptoms, such as acute abdominal cramping. Researchers examined the time required for a person to report a specific change in pain and the need for further pain-relieving agents in the hours following administration.

Studies report how symptoms evolved in the observed populations, indicating patterns observed in the studies related to acute visceral spasms. Findings describe patterns observed in the studies, which often focused on outcomes reflecting episodic or acute changes. What remains uncertain is the role of the compound when compared against other analgesic mechanisms in the acute setting, particularly for specific causes of non-specific abdominal pain.


Evidence for Irritable Bowel Syndrome (IBS) Symptoms

Placebo-controlled RCTs and systematic reviews were applied in studies examining patient-reported experiences for conditions characterized by fluctuating manifestations, such as IBS. Researchers examined patient-reported outcomes describing perceived discomfort and the overall global assessment of whether symptoms evolved over the study period.

Studies report how symptoms evolved in the observed populations, with some trials describing patterns observed in the studies where differences were observed in the proportion of participants who reported symptom change compared to those receiving an inactive substance (placebo). Evidence for maintenance or long-term outcomes (beyond a few months) is limited, meaning long-term effects are not fully established.


Evidence for Use in Diagnostic and Endoscopic Procedures

This evidence consists of comparative clinical studies and RCTs focused on procedural outcomes. The medicine was studied for its role in diagnostic procedures, where reducing muscle movement in the digestive tract is required to improve visualization. Research examined outcomes related to systemic or functional imbalance by monitoring objective procedural metrics, including the clarity of diagnostic image quality and how well organs were visualized.

The evidence describes a documented pattern in reducing gastrointestinal motility to facilitate imaging and visualization. However, comparative evidence is lacking regarding the optimal timing and dose of administration for every specific type of imaging modality, and data are still emerging for its role in newer imaging technologies.

Frequently Asked Questions (FAQ)

Common questions about Buscol (FAQ)


Q: How quickly should I expect Buscol to start working?

Official regulatory documents indicate that the oral tablet typically begins to show its therapeutic effects on the gut muscles within 15 to 30 minutes after ingestion. The injection form is designed to act much more rapidly for acute needs.

Q: What is the typical duration of effect for one dose of Buscol?

According to the official product information, the effect of one oral dose of the active ingredient, Hyoscine Butylbromide, generally lasts for approximately 4 to 6 hours. This duration is consistent with the recommended dosing frequency described in regulatory documents.

Q: Is Buscol known to cause drowsiness or dizziness?

Official safety data lists dizziness as an uncommon side effect (affecting less than 1 in 100 people). Some regulatory patient information also notes that drowsiness may occur. Regulatory warnings highlight the importance of recognizing these potential effects.

Q: Can Buscol affect my ability to drive or operate machinery?

Yes, official guidance explicitly warns that side effects such as dizziness or visual disturbances (like difficulty focusing) may affect your ability to drive or use heavy machinery. Regulatory documents state that if these effects occur, driving or operating machinery should be avoided.

Q: Are there any major diet or food restrictions while taking Buscol?

Official administration instructions confirm that Buscol tablets may be taken with or without food. Standard regulatory documents do not typically list specific warnings or restrictions regarding major food or beverage interactions.

Q: Can Buscol be used for period pain (menstrual cramps)?

The active ingredient in Buscol is indicated for the relief of spasms in the smooth muscle of the genito-urinary tract, which includes the uterus. In some regions, certain combination products containing the active ingredient are officially indicated for the relief of pain associated with menstrual cramps.

Q: What research evidence supports the use of Buscol for Irritable Bowel Syndrome (IBS) symptoms?

Studies and systematic reviews have examined the use of the active ingredient for IBS symptoms. Evidence indicates that its use may be associated with a greater proportion of participants reporting overall symptom relief, especially for abdominal pain, compared to those receiving a placebo. Data concerning the long-term effectiveness of the drug is generally limited.

Q: Is it safe for older adults to use Buscol?

Official warnings advise that caution is required for older adults. This is because they may be more sensitive to the anticholinergic effects of the drug, which can increase the risk of side effects such as urinary retention or confusion.

Q: Is it safe to take Buscol with alcohol?

Official product documents generally do not list a direct chemical interaction warning with alcohol. However, because the medicine can cause effects like dizziness and drowsiness, concomitant use with alcohol may potentially intensify these particular side effects.

Q: What is the typical age range for children allowed to use Buscol?

Regulatory documents state that oral tablets are generally not recommended for children under 6 years of age. For children 6 years and older, the dose is determined based on the adult minimum dose, but use of the medicine, particularly in children, is subject to clinical assessment.

Q: Can people who have had bowel surgery or have stomas use Buscol?

Buscol is contraindicated (not recommended) in patients with conditions that involve mechanical obstructions or severe enlargement of the bowel. Regulatory documents note that use in patients with a history of bowel surgery or potential mechanical issues requires clinical assessment, as the medicine is contraindicated in cases of obstruction or ileus.

Q: What is the difference between Buscol and Mebeverine (or a similar drug)?

Both Buscol and Mebeverine are classified as antispasmodics, but they have distinct mechanisms. Official documentation states that Buscol is an anticholinergic agent that blocks nerve signals, while Mebeverine is generally described as a direct smooth muscle relaxant and is not primarily anticholinergic.

Q: Is Buscol the same as Scopolamine?

No, Buscol is not the same as scopolamine. The active ingredient in Buscol, Hyoscine Butylbromide, is a semi-synthetic derivative of scopolamine. Its specialized chemical structure is designed to limit its action primarily to the abdominal area, preventing it from crossing the blood-brain barrier like scopolamine can.

Q: Can Buscol be taken every day, or only when cramps occur?

Regulatory guidelines constrain the medicine to short-term symptomatic management. It is explicitly advised that the tablets should not be taken continuously on a daily basis for prolonged periods unless the cause of the pain has been investigated and the long-term use is advised by a healthcare professional.

Q: Is Buscol an over-the-counter (OTC) medicine in most places?

The legal status of Buscol varies significantly by country. In certain regions, the 10 mg oral tablet is available over-the-counter (OTC) or as a pharmacy-only medicine. In other major markets, the drug is classified strictly as prescription-only.

Q: Do any herbal supplements or vitamins interact with Buscol?

Official documentation does not specifically name interactions with common herbal supplements or vitamins. However, regulatory guidance suggests that individuals communicate the use of all products, including herbal remedies or supplements, to a healthcare professional, due to the potential for unforeseen interactions.

Q: What happens if I miss a dose of Buscol?

Official patient instructions describe the procedure for a missed dose. If a dose is forgotten, regulatory documents state it should be taken as soon as remembered, unless the next scheduled dose is nearly due, in which case the missed dose is skipped. It is explicitly advised not to take a double dose to compensate.

Q: Does Buscol come in different strengths, like Buscol Forte?

Yes, the active ingredient is available in different strengths. The oral tablets are typically available as 10 mg and 20 mg doses. In some regions, the 20 mg tablet is indeed marketed under a 'Forte' variation. The solution for injection is usually 20 mg/mL.

Q: Can Buscol cause problems for people with an overactive thyroid gland?

Official warnings advise that Buscol should be used with caution in individuals with an overactive thyroid gland (hyperthyroidism). This is because the medicine may cause an increased heart rate (tachycardia), a condition also associated with thyroid hyperactivity.

Q: Is it possible for a painful, red eye to be a side effect of Buscol?

Yes, a painful, red eye with loss of vision is listed in regulatory documents as a rare but serious side effect that requires immediate medical attention. This symptom can be a sign of increased pressure in the eye, which can be triggered by anticholinergic agents like Buscol in susceptible individuals.

Q: What happens if Buscol is taken with certain asthma inhalers?

Official interaction warnings state that the anticholinergic effect of Buscol may be intensified when taken with other anticholinergic medicines. This includes drugs like tiotropium and ipratropium, which are active ingredients found in some inhaled medicines used for chronic respiratory diseases.

How should Buscol be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory labeling dictates specific storage and disposal requirements for Buscol (Hyoscine Butylbromide) to maintain product integrity and safety.

Storage Category Requirement (Official Labeling)
Temperature Tablets: Store below 30 C (or 25 C in some regions) and protect from moisture. Injection: Store at controlled room temperature (15 C to 30 C).
Container Rule Tablets must be kept in the original pack to protect from environmental factors and light.
Stability Injection ampoules are for single use only; any unused portion must be immediately discarded.
Child Safety The medication must be stored out of the sight and reach of children.
Disposal Unused or expired product must be disposed of according to local regulations; do not throw away in household waste or flush down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Buscol found in:

A-Z Index: